Search Bar & Filters
Found 32 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying KK8123 in adults with X-linked hypophosphatemia XLH to evaluate its safety, tolerability, pharmacokinetics PK, and pharmacodynamics PD. This Phase 12, multicenter, open-label study includes a screening period, dose escalation, and an optional safety extension. The goal is to understand how KK8123 behaves in the body and its effects on XLH symptoms. Participants will receive subcutaneous doses of KK8123 in escalating amounts during Part 1, which includes a treatment period followed by observation. Part 2 offers an optional extension to continue safety monitoring. Doses range from low to mid-high levels, and the study assesses various biological markers and labs over a period of up to 48 weeks. During the trial, participants undergo regular assessments including blood tests for phosphorus levels, hematology, clinical chemistry, hormone levels, vital signs, echocardiograms, and renal ultrasounds. Researchers monitor for treatment-emergent adverse events and measure drug concentration levels. The study lasts up to 48 weeks with continuous safety and efficacy monitoring throughout the treatment and extension phases.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
This research aims to learn about the safety and effects of a medicine called ritlecitinib for treating moderate alopecia areata AA, a condition causing patchy hair loss. The study includes participants aged 12 years and older who have had patchy hair loss for at least 6 months but not more than 10 years, without other causes of hair loss. It is a phase 3 randomized, double-blind, placebo-controlled trial designed to evaluate ritlecitinib in adolescents and adults with AA. Participants will be randomly assigned to receive either ritlecitinib 50 mg or placebo once daily by mouth for 24 weeks. After this, depending on their response, their treatment may remain the same or change to either 50 mg or 100 mg ritlecitinib for another 23 weeks. Those receiving placebo initially may also be switched to ritlecitinib during this second period. Treatments are taken at home, and the study includes multiple groups based on response to treatment. Participants will be involved for about 57 weeks, including study visits at the clinic and some phone check-ins. Researchers will monitor hair loss using the Severity of Alopecia Tool SALT and other assessments like eyebrow and eyelash evaluations, patient satisfaction, and emotional impact. Safety will be closely monitored through adverse event tracking and laboratory tests. A follow-up visit about 4 weeks after the last dose will check on participants health.
Actively Recruiting
Researchers are evaluating the safety and effects of ritlecitinib, a medicine taken by mouth, for treating alopecia areata, a condition causing hair loss on the scalp, face, and other body areas. This study focuses on people 12 years and older who have lost 50% or more of their scalp hair and do not have other causes of hair loss. The study aims to compare two doses, 50 mg and 100 mg, of ritlecitinib and see if the higher dose is safe and effective. Participants in Part 1 are randomly assigned to receive either 50 mg or 100 mg of ritlecitinib once daily, with some re-randomization at 24 weeks based on their response. Part 2 includes adolescents aged 12 to less than 18 years who receive 100 mg once daily. The study compares these doses to each other and to data from previous studies without a placebo group within this trial. Participants take the study medicine by mouth daily for up to 48 weeks depending on their group. During the approximately 13-month study, participants visit the study site up to nine times for assessments including alopecia areata evaluations, physical exams, hearing tests, blood tests, chest X-rays, electrocardiograms, and scalp and eye photographs Part 1 only. They also complete questionnaires about their condition. Researchers measure hair loss severity using the Severity of Alopecia Tool SALT, monitor side effects, laboratory results, and overall safety throughout the trial.
Actively Recruiting
Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of orforglipron in adult women with stress urinary incontinence SUI who are overweight or have obesity. SUI is characterized by leaking urine during activities such as coughing or exercising. This phase 3 study aims to compare orforglipron to a placebo in this specific population. Participants will be randomly assigned to receive either orforglipron or a placebo orally. The study follows a parallel design with double masking and includes two independent groups. Treatment and assessments will occur over approximately 58 weeks, including screening, treatment, and safety follow-up. During the trial, participants will undergo evaluations to measure changes in the frequency of incontinence episodes, body weight, quality of life specific to urinary incontinence, use of continence pads, patient impression of condition, cholesterol levels, and waist circumference from baseline to week 52. Safety monitoring will continue through the follow-up period to assess any treatment-related effects.
Actively Recruiting
This research aims to collect and analyze long-term safety and effectiveness data for palovarotene in people with fibrodysplasia ossificans progressiva FOP, a very rare and disabling condition characterized by abnormal bone growth in soft tissues. Participants include children and adults, some already treated with palovarotene and others untreated. The study will compare safety outcomes and effectiveness between these groups in real-world settings. Participants will either continue receiving palovarotene as prescribed by their doctors or remain untreated with this medication. The study will observe these two groups over time, documenting flare-ups, growth, bone fractures, and physical function. Data collection will include information on daily activities and physical performance related to FOP and palovarotene treatment. During the study, participants will have assessments such as joint involvement scales, lung function tests, physical function questionnaires, and reports on flare-ups and fractures. These evaluations will occur at baseline and regularly up to eleven years. Safety monitoring includes treatment-emergent adverse events and pregnancy outcomes, with follow-up on babies born to participants. Overall, the study follows participants from baseline up to 11 years, providing comprehensive long-term data.
Actively Recruiting
Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of canvuparatide, a once-weekly injectable treatment, for adults with hypoparathyroidism, a condition characterized by low parathyroid hormone levels. This Phase 3 trial compares canvuparatide with a placebo to determine its impact on patients who have had the condition for at least 12 months. Participants will receive either canvuparatide or a placebo, both given via a single-use drug-device combination that delivers a 1 mL subcutaneous injection once a week. The study includes a randomized, double-blind design with parallel groups and will be followed by an open-label extension phase. Dosages vary from 400 to 1600 micrograms per milliliter of the drug in the delivery device. During the study, participants will have regular visits to monitor their response to treatment, including measurements of calcium levels and parathyroid hormone. The main outcome is the proportion of patients who respond to treatment at 26 weeks. Safety and efficacy will be closely assessed throughout the trial, which is expected to continue until 2029. Participants health will be monitored to ensure proper management of hypoparathyroidism and to track any side effects.
1-10 of 32
1